4Soupart A, Penninckx R, Crenier L, et al. Prevention of brain demyelination in rats after excessive correction of chronic hyponatremia by serum sodium lowering. Kidney Int, 1994,45: 193-200.
5Sterns RH, Silver SM. Hemodialysis in hyponatremia: is there a rish? Semin Dial, 1990;3:3
6Oh MS, Kim HJ, Carroll HJ. Recommendations for treatment of symptomatic hyponatremia. Nephron, 1995, 70: 143-150.
7Soupart A, Ngassa M, Decaux G. Therapeutic relowering of serum sodium in a patient after excessive correction of hyponatremia. Clin Nephrol, 1999,51:383-386.
8Fried LF, Palevsky PM. Hyponatremia and hypernatremia. Med Clin North Am, 1997,81:585-609.
9Yamamura Y, Ogawa H, Yamashitat H, et al. Characterization of a novel aquaretic agent, OPC 31260, as an orally effective,nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol,1992, 105: 787-791.
10Serradeil-Le Gal C, Wagnon J, Valette G, et al. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res,2002, 139: 197-210.
4Ginès P,Càrdenas A,Schrier RW.Liver disease and the kidney.In:Schrier RW,editor.Diseases of the Kidney&Urinary Tract.Philadelphia:Lippincott Williams&Wilkins,2007:2179-2205.
5Jalan R,Hayes PC.Sodium handling in patients withwell compenstateed cirrhosis is dependent on the severity of liver disease and portal pressure.Gut,2000,46:527-533.
